Beactica Therapeutics AB, a Swedish precision medicine company, announced the selection of BEA-28 as a preclinical candidate for its TEAD programme, which ...
Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background Administered...
AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBM...
Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, announced positive results from a prospective, multicenter randomized controlled tr...
Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duratio...
SkinHealth Systems (Nasdaq: SKIN), home to flagship brand Hydrafacial™, announced the European expansion of the SkinStylus® SteriLock® MicroS...
Phase 1 study is evaluating the safety, tolerability and pharmacokinetics of Mironid’s lead LoAc® small molecule in healthy volunteers Dosing ...
Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in dela...
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in a...
EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts. EGL-003 produced selective, dose-dependent Treg expansion without am...
Terumo Neuro announced that it has signed an agreement to acquire Arsenal Medical Inc., a privately held, clinical-stage biomaterials company developing Ne...
KIT2014 is a novel inhaled peptide therapy being developed for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronch...
InSilicoTrials, a cloud-based platform for AI and computational modeling and simulation in healthcare, today announced that it is a subawardee on a team ...
Marsico Pancreatic Cancer Initiative at CU Anschutz expands across institutions, pairing single-cell and spatial profiles with longitudinal outcomes fr...
© 2026 Biopharma Boardroom. All Rights Reserved.
